Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy - Wikidata - awgldk - TriplyDB

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

http://www.wikidata.org/entity/Q34945403

about

Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel Electrocardiographic Changes and Arrhythmia in Fabry Disease Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease Fabry disease in latin america: data from the fabry registry.Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).Genetic screening of Fabry patients with EcoTILLING and HRM technology.Stroke and Fabry disease.Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications Hypertension in adult Fabry's disease: is cardiotrophin-1 a diagnostic biomarker?Fabry disease and early stroke Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Fabry disease: the many faces of a single disorder.The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.Prevalence of symptoms in female Fabry disease patients: a case-control survey.A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Gastrointestinal Symptoms of Patients with Fabry Disease.Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis.

P2860

Q21261394-7AADEDE0-C3F1-4694-A34B-509FD6B6F4EE Q26751508-A21FF406-0761-4614-9C60-56409B2FC1F6 Q28730130-B5712F7E-02A7-41D5-907B-392C38B3C3A7 Q30592389-3FAFDC5B-5AEA-4313-B5F8-39797F28A344 Q30632134-6E17A322-09E2-4B5F-B2AC-21FE626CC1F4 Q33645550-26DF90D6-9136-413C-836A-96F7455783E4 Q33652370-9B305E34-B986-4004-A8A6-A0F89C687000 Q33683158-D83C0886-4FB6-4764-96B6-B2EC14BABDE7 Q33726258-8261AA77-872A-4B8A-ACE9-6DC5ADD93C0C Q33730412-3F93CAEF-9AA0-493E-80F0-3AFA437DDAB2 Q33737225-865FC222-691A-42E6-ADEC-EEF4B72B60A3 Q33776219-D5A88213-5E17-4A7C-BF52-9481C5528A99 Q33835524-AD9B6532-E78A-403E-BE37-580E7D1E4302 Q33866320-01BD1CD4-79F9-4DE6-A921-8AC70CB94F0E Q33886219-8A92B917-ADB9-4E71-983E-4D94BD08FC68 Q33988780-69EBDEBC-7237-4BCE-9BEF-BDDC2C7CEBC5 Q34012395-A1232D83-B9F8-4CDE-8769-1686F44F7B4B Q34061632-97B18A78-3A37-4398-9A91-DCB9E7F324B0 Q34103791-EA2554DE-2F88-4004-866B-F11F3314E451 Q34456578-E5CA4346-959D-4574-B3D7-2BD46CCA8E57 Q34659532-8480BAB6-A8A9-4BE1-81D9-5ED44CC0F146 Q34739186-952971D5-5A79-4D2F-BEA7-3F659AAC8896 Q34805283-791D5295-20A3-4D7E-936D-19E4986836F0 Q34976618-5D05CEC6-DFBB-4A04-9F9D-321D0E5EEF27 Q35110216-9CB4355C-EA1E-41B1-94E1-00D2ACEBB6BC Q35550696-D0B27DEE-3404-4167-A0A7-DAF8E1DC353C Q35587768-EACDA6C5-5513-4100-BB21-D3A6B0566B34 Q35608422-7CF462B6-6B39-474D-AB98-152B81B6120D Q35692435-7492AA52-F520-4A68-AF94-6293778B1ACA Q35788989-98D19618-C3BC-45AE-A629-F94C0DB8E533 Q35848678-BB40B819-878E-4AA1-B199-C675F5CBE88B Q36105190-6C028E66-3D2B-4D6E-8A6E-E3B571FDC1E7 Q36193984-01576615-E18E-4D8A-8C8D-EB30EBAAD04E Q36203469-4D239908-AB0F-4B38-A744-8D9761B9BEE8 Q36272033-C80B5CBC-B6EB-40EE-9E54-7F1916FE2185 Q36309032-6DCB8CD5-60CB-4C1B-AD0F-6D509CA823E6 Q36475780-6CF48B46-24AA-4B4D-AC09-7FC89188356E Q36529707-9ABF2081-EA4D-422F-BB14-E77694262D4A Q36571559-FC509364-BA57-4D7F-A089-77BC2094CCDC Q36682177-6FC7825D-4B5C-42E5-A0AF-56F9646BD308

P2860

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

http://www.wikidata.org/entity/Q34945403

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fabry disease: progression of ...... ore enzyme replacement therapy

@ast

Fabry disease: progression of ...... ore enzyme replacement therapy

@en

Fabry disease: progression of ...... ore enzyme replacement therapy

@nl

type

label

Fabry disease: progression of ...... ore enzyme replacement therapy

@ast

Fabry disease: progression of ...... ore enzyme replacement therapy

@en

Fabry disease: progression of ...... ore enzyme replacement therapy

@nl

prefLabel

Fabry disease: progression of ...... ore enzyme replacement therapy

@ast

Fabry disease: progression of ...... ore enzyme replacement therapy

@en

Fabry disease: progression of ...... ore enzyme replacement therapy

@nl

P1433

Q34945403-EA34D45D-1266-4556-9F4C-96025454AA9C

P1476

Q34945403-542B68C6-CACF-44CA-9940-155BB280674C

P2093

Q34945403-1B27C988-D834-4E65-86CA-519C9E5FD194

Q34945403-26D517D5-2028-44E3-8859-5F31CDCDB23C

Q34945403-30A6B9DA-1C18-4E74-A638-3B45E4F5FA21

Q34945403-3F1EC7EE-7AF7-4085-BCC0-76295612FD8D

Q34945403-55BCFF20-E8FB-4D3B-92E1-9D1EB33826B1

Q34945403-65EA1423-6F96-48E4-A562-72FFF7E1CDCF

Q34945403-8F5B76A0-EC96-4426-9A5C-C64DD33288D3

Q34945403-930FE868-35B7-46B3-B5A2-F9FADE36DDFD

Q34945403-C2D3CE99-6B2C-47EE-ABE6-33AC99684950

P2860

Q34945403-0184DBD7-8D98-4F7A-B9CE-113B477131A4

Q34945403-116B54A6-CE13-4432-9BBF-F552EFD4422E

Q34945403-1C221F03-FB80-4E59-908F-21A0BE1C15B4

Q34945403-32278355-4AD9-470E-8717-136143BA0896

Q34945403-5CAD35C7-64DA-4EF8-ABAF-D60D0B64E00F

Q34945403-76A3D96E-30C2-4AF8-9015-A074D09A0C64

Q34945403-7ACAD71D-C486-400F-A154-CD915DBA0A08

Q34945403-84897D4D-4A80-4A86-B4E7-CA05F79CA511

Q34945403-887F53E2-2F1F-4394-838A-A5E16DDDA800

Q34945403-8B39E6F7-5F47-4A41-A32B-3FA399F7F456

P304

Q34945403-1F31E7C5-6F8A-4346-86A7-4478246C0016

P31

Q34945403-DE82E925-D79B-46FA-9234-A20379DA301C

P356

Q34945403-4BE20502-D37A-4ED7-8B13-64A705CB327F

P407

Q34945403-F685E9BB-AE7E-4DFB-960E-A9FEB494A5C6

P433

Q34945403-5E8E4AD8-834F-4DF1-A91C-2EDEA4C6DD54

P478

Q34945403-AC09051C-BE26-4A15-AAD6-FC103B8CB22C

P577

Q34945403-580B285D-C6D0-4ED5-95A7-D261984E45F1

P5875

Q34945403-C34CE7A9-90EC-48C1-B4BD-4F328BA00ED5

P698

Q34945403-EB4E4315-122C-4828-890E-08EBB13963B8

P921

Q34945403-0A501FFF-D8D0-4035-AF60-3FD1005799AC

P932

Q34945403-80F9A189-A676-46A7-BAA6-D7E89922DA89

P356

P1433

Nephrology Dialysis Transplantation

P1476

Fabry disease: progression of ...... ore enzyme replacement therapy

@en

P2093

David G Warnock

http://www.w3.org/2001/XMLSchema#string

Gabor E Linthorst

http://www.w3.org/2001/XMLSchema#string

Jan Bultas

http://www.w3.org/2001/XMLSchema#string

Maryam Banikazemi

http://www.w3.org/2001/XMLSchema#string

Raphael Schiffmann

http://www.w3.org/2001/XMLSchema#string

Robert J Desnick

http://www.w3.org/2001/XMLSchema#string

Seymour Packman

http://www.w3.org/2001/XMLSchema#string

Sven Asger Sorensen

http://www.w3.org/2001/XMLSchema#string

William R Wilcox

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

CNS manifestations of Fabry's disease.

Renal pathological changes in Fabry disease.

Renal disease in Fabry patients.

Assessing kidney function--measured and estimated glomerular filtration rate.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

P304

2102-2111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFP031

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24011787

http://www.w3.org/2001/XMLSchema#string

P698

19218538

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

2698092

http://www.w3.org/2001/XMLSchema#string